Efficacy of a second interleukin-17 inhibitor in psoriasis patients
DOI:
https://doi.org/10.47196/da.v27i2.2233Keywords:
efficacy, second interleukin-17 inhibitor, psoriasisAbstract
Among the many biological treatments for psoriasis, interleukin-17 (IL-17) inhibitors are safe and highly effective. Despite this, sometimes it is necessary to change the treatment. The efficacy of an IL-17 inhibitor was evaluated in patients who had suffered primary or secondary failure to treatment with another IL-17 inhibitor. The clinical trials analyzed did not show differences in efficacy between patients who had never received treatment and those already medicated with another IL-17 inhibitor. In clinical practice, the efficacy is slightly lower in those already treated with biological drugs.
References
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Argentine Society of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
